Prostate Cancer - Results from #1940

MYC is a regulator of androgen receptor inhibition-induced metabolic requirements in prostate cancer. October 12, 2023

Long-term quality-of-life outcomes following prostate radiotherapy with or without high-dose-rate brachytherapy boost: post-hoc analysis of TROG 03.04 RADAR. October 12, 2023

Chronic Glucocorticoid Use and Risk for Advanced Prostate Cancer at Presentation: A SEER-Medicare Cohort Study. October 12, 2023

A New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer. October 12, 2023

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer October 11, 2023

Surgery with or Without Darolutamide in High-risk and/or Locally Advanced Prostate Cancer: The SUGAR (CCAFU-PR2) Phase 2 Trial Rationale and Protocol. October 11, 2023

A geometry and dose-volume based performance monitoring of artificial intelligence models in radiotherapy treatment planning for prostate cancer. October 11, 2023

Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial. October 11, 2023

A Phase 1, Open-label, Dose-Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer. October 11, 2023

Adrenal Metastases Are Associated with Poor Outcomes in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Nivolumab in the GETUG-AFU-26 NIVOREN Phase 2 Trial. October 11, 2023

Development of Bag-1L as a therapeutic target in androgen receptor-dependent prostate cancer. October 11, 2023

Artificial Intelligence-Based PTEN Loss Assessment as an Early Predictor of Prostate Cancer Metastasis After Surgery: A Multicenter Retrospective Study October 10, 2023

First Patient Treated with Cu-67 SAR-Bombesin in Theranostic Prostate Cancer Trial October 10, 2023

Clinical and Functional Analyses of an African-ancestry Gain-of-function HOXB13 Variant Implicated in Aggressive Prostate Cancer. October 10, 2023

Impact of persistent PSA after salvage radical prostatectomy: a multicenter study. October 10, 2023

COmparing Urolift and Standard Transurethral resection of prostate Ahead of Radiotherapy in men with urinary symptoms secondary to prostate enlargement in Southwest London and North Cumbria (CO-STAR): a study protocol for a randomised feasibility study. October 10, 2023

TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment. October 10, 2023

ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy. October 10, 2023

Deep Learning-Based T2-weighted MR Image Quality Assessment and Its Impact on Prostate Cancer Detection Rates. October 10, 2023

A Canadian center's experience on whole-gland salvage therapy for radio-recurrent prostate cancer with various modalities. October 9, 2023

Page 98 of 1435